122 related articles for article (PubMed ID: 19271333)
1. Report from the 2008 joint ICAAC/IDSA meeting. Darunavir and atazanavir: 96-week data from ARTEMIS and CASTLE.
Sax PE
AIDS Clin Care; 2008 Dec; 20(12):98. PubMed ID: 19271333
[No Abstract] [Full Text] [Related]
2. Anti-HIV agents. The Castle study: lopinavir vs. atazanavir.
TreatmentUpdate; 2008 Mar; 20(2):7-8. PubMed ID: 18661646
[No Abstract] [Full Text] [Related]
3. Report from the 13th retrovirus conference. Extending the role of atazanavir.
Feinberg J
AIDS Clin Care; 2006 Apr; 18(4):38. PubMed ID: 16718882
[No Abstract] [Full Text] [Related]
4. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir--the ARTEN Study.
Sax PE
J Watch AIDS Clin Care; 2009 Oct; 21(10):80. PubMed ID: 20458811
[No Abstract] [Full Text] [Related]
5. Atazanavir: clinical use.
Bartlett JG
Hopkins HIV Rep; 2003 Jul; 15(4):3-4. PubMed ID: 14696561
[No Abstract] [Full Text] [Related]
6. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
[No Abstract] [Full Text] [Related]
7. [Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain].
Smets E; Brogan AJ; Hill A; Adriaenssen I; Sawyer AW; Domingo-Pedrol P; Gostkorzewicz J; Ledesma F
Enferm Infecc Microbiol Clin; 2013; 31(7):430-6. PubMed ID: 23260386
[TBL] [Abstract][Full Text] [Related]
8. Meeting report. Report from ICAAC.
Sax PE
AIDS Clin Care; 2006 Dec; 18(12):111-2. PubMed ID: 17228446
[No Abstract] [Full Text] [Related]
9. Anti-HIV agents. Atazanavir vs. Kaletra.
TreatmentUpdate; 2005; 17(1):3-4. PubMed ID: 17225314
[No Abstract] [Full Text] [Related]
10. PI monotherapy effective as maintenance.
AIDS Patient Care STDS; 2005 Oct; 19(10):696. PubMed ID: 16232054
[No Abstract] [Full Text] [Related]
11. Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
Santos JR; Moltó J; Llibre JM; Pérez N; Capitán ; Miranda C; Clotet B
HIV Clin Trials; 2009; 10(3):129-34. PubMed ID: 19632951
[TBL] [Abstract][Full Text] [Related]
12. [HIV infection. Compatibility of recent protease inhibitors in direct comparison - the advantage of DRV].
MMW Fortschr Med; 2014 Jun; 156 Suppl 1():52. PubMed ID: 25026859
[No Abstract] [Full Text] [Related]
13. Boosted Reyataz: 48-week results.
Huff B
GMHC Treat Issues; 2004; 18(1-2):15. PubMed ID: 15119279
[No Abstract] [Full Text] [Related]
14. Reviving protease inhibitors: new data and more options.
Murphy RL
J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S43-52; quiz S53, S55-6. PubMed ID: 12946064
[No Abstract] [Full Text] [Related]
15. Drug profile: atazanavir (Reyataz, ATV).
Pham PA
Hopkins HIV Rep; 2003 Jul; 15(4):4-5. PubMed ID: 14696562
[No Abstract] [Full Text] [Related]
16. New protease inhibitor TMC-114. Preliminary 24-week late breaker results of the phase II trial.
Berger DS
Posit Aware; 2005; 16(2):27, 41. PubMed ID: 15828108
[No Abstract] [Full Text] [Related]
17. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
[TBL] [Abstract][Full Text] [Related]
18. Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
Martinez E; Gonzalez-Cordon A; Ferrer E; Domingo P; Negredo E; Gutierrez F; Portilla J; Curran A; Podzamczer D; Murillas J; Bernardino JI; Santos I; Carton JA; Peraire J; Pich J; Perez I; Gatell JM;
HIV Med; 2014 Jul; 15(6):330-8. PubMed ID: 24417772
[TBL] [Abstract][Full Text] [Related]
19. HIV protease inhibitors: recent clinical trials and recommendations on use.
Fernández-Montero JV; Barreiro P; Soriano V
Expert Opin Pharmacother; 2009 Jul; 10(10):1615-29. PubMed ID: 19527188
[TBL] [Abstract][Full Text] [Related]
20. Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Atazanavir--booster of the future?
TreatmentUpdate; 2003; 15(3):5-6. PubMed ID: 17219613
[No Abstract] [Full Text] [Related]
[Next] [New Search]